Skip to main content

Advertisement

Log in

Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose: To characterize the population pharmacokinetics of trastuzumab in patients with metastatic breast cancer. Methods: A nonlinear mixed effect model was based on pharmacokinetic data from phase I, II, and III studies of 476 patients. The phase I study enrolled patients with advanced solid tumors. The phase II and III studies enrolled patients with HER2-positive metastatic breast cancer. Patients in the pivotal phase II and III studies were treated with a 4 mg/kg loading dose of trastuzumab followed by 2 mg/kg weekly for up to 840 days. The model adequately predicted observed trastuzumab concentrations. Model stability and performance were verified using bootstrap simulations. Percentiles, mean, and standard deviation of observed levels were compared with their distributions from 100 replicates of datasets simulated under the model. Results: A two-compartment linear pharmacokinetic model best described the data and accounted for the long-term accumulation observed following weekly administration of trastuzumab. Population estimates from the base model for clearance (CL) and volume of distribution of the central compartment (V1) of trastuzumab were 0.225 L/day, and 2.95 L, respectively. Estimated terminal halflife (t1/2) based on the population estimate was 28.5 days. Interpatient variabilities in clearance and volume were 43 and 29%, respectively. The number of metastatic sites, plasma level of extracellular domain of the HER2 receptor, and patient weight were significant baseline covariates for clearance, volume, or both (P<0.005). However, these covariate effects on trastuzumab exposure were modest and not clinically important in comparison with the large inter-patient variability of CL. Concomitant chemotherapy (anthracycline plus cyclophosphamide, or paclitaxel) did not appear to influence clearance. Conclusion: This population pharmacokinetic model can predict trastuzumab exposure in the long-term treatment of patients with metastatic breast cancer and provide comparison of alternative dosage regimens via simulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L et al (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737–744

    CAS  PubMed  Google Scholar 

  2. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D et al (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659–2671

    CAS  PubMed  Google Scholar 

  3. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al (1999) Multinational study of the efficacy and safety of humanized monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648

    CAS  PubMed  Google Scholar 

  4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    CAS  PubMed  Google Scholar 

  5. 2003 Herceptin Package Insert

  6. 2003 Herceptin Biological License Application (BLA)

  7. Payne RC, Allard JW, Anderson-Mauser L, Humphreys JD, Tenney DY, Morris DL (2000). Automated assay for HER-2/neu in serum. Clin Chem 42:175–182

    Google Scholar 

  8. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41

    CAS  PubMed  Google Scholar 

  9. Beal SL, Boeckman A, Sheiner LB (1988–1992) NONMEM user’s guides. University of California at San Francisco, San Francisco

  10. Wählby U, Jonsson EN, Karlson MO (2001) Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28:231–252

    PubMed  Google Scholar 

  11. Gobburu JVS, Lawrence J (2002) Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: some Inferences. Pharm Res 19:92–98

    CAS  PubMed  Google Scholar 

  12. Ette EI (1997) Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37:486–495

    CAS  PubMed  Google Scholar 

  13. Parke J, Holford NH, Charles BG (1999) A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 59:19–29

    CAS  PubMed  Google Scholar 

  14. Gelman A, Meng XL, Stern H (1996) Posterior predictive assessment of model fitness via realized discrepancies. Statistica Sinica 6:733–807

    Google Scholar 

  15. Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28:171–192

    Article  CAS  PubMed  Google Scholar 

  16. Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R et al (2003) Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21:3965–3971

    CAS  PubMed  Google Scholar 

  17. Trang JM (1992) Pharmacokinetics and metabolism of therapeutic and diagnostic antibodies. In: Ferraiolo BL, Mohler MA, Gloff CA (eds) Protein pharmacokinetics and metabolism. Pharmaceutical biotechnology, vol 1. Plenum Press, New York, pp 223–270

  18. Albanell J, Codony J, Lopez-Talaver J, Arribas J, Baselga J (1999) Inhibition of HER2 extracellular domain shedding by metalloprotease inhibitors and by Herceptin in breast cancer cells. Proc Am Soc Clin Oncol 18:2381

    Google Scholar 

  19. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726

    CAS  PubMed  Google Scholar 

  20. Leyland-Jones B, Marty M, Baselga J, Gatzemeier U, Barton C, Lennon S (2004) Effects of trastuzumab (H) and chemotherapy on circulating HER2 extracellular domain (ECD) in patients with metastatic breast cancer (MBC) and non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 23:19

    Google Scholar 

Download references

Acknowledgements

The authors thank Dr Judy A. Fox and Dan Combs (Genentech, Inc.) for sharing their expertise in antibody biology and pharmacokinetics and Drs Virginia Paton, David Allison, Leonard Reyno and Daniel Spyker (Genentech, Inc.) and Dr Jean-Louis Steimer (Roche) for their review of the analysis and insightful comments.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jian-Feng Lu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bruno, R., Washington, C.B., Lu, JF. et al. Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56, 361–369 (2005). https://doi.org/10.1007/s00280-005-1026-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-005-1026-z

Keywords

Navigation